This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Calcipotriol with betamethasone topical


Topical formulations containing calcipotriol (as calcipotriol hydrate) and betamethasone (as betamethasone dipropionate).

Drugs List

  • calcipotriol 50microgram/g and betamethasone dipropionate 500microgram/g cream
  • calcipotriol 50microgram/g and betamethasone dipropionate 500microgram/g foam
  • calcipotriol 50microgram/g and betamethasone dipropionate 500microgram/g gel
  • calcipotriol 50microgram/g and betamethasone dipropionate 500microgram/g ointment
  • DALBECAL 50microgram+500microgram/g ointment
  • DALONEV ointment
  • DOVOBET gel
  • DOVOBET ointment
  • ENSTILAR 50microgram+500microgram/g cutaneous foam
  • WYNZORA 50microgram+500microgram/g cream
  • Therapeutic Indications


    Plaque psoriasis
    Psoriasis - scalp

    Ointment and foam
    Topical treatment of stable plaque psoriasis vulgaris amenable to topical therapy.

    Topical treatment of scalp psoriasis.
    Topical treatment for mild to moderate "non scalp" plaque psoriasis vulgaris.

    Topical treatment of mild to moderate psoriasis vulgaris including scalp psoriasis.



    Ointment and foam
    One application to the affected area once daily. The maximum daily dose is 15g, the recommended treatment period is 4 weeks and the treated area should not be more than 30% of the body surface.

    Long-term maintenance treatment (foam formulation)
    Patients that respond at 4 weeks' treatment are suitable for long-term maintenance treatment.
    One application twice weekly on two non-consecutive days to areas previously affected. Between applications there should be 2 to 3 days without treatment.

    For treatment of the scalp
    Apply 1g to 4g daily (4g corresponds to one teaspoonful). The recommended treatment period is 4 weeks. Shampoo off after leaving on the scalp overnight or during the day, not recommended to take a shower, bath or to wash hair before.

    For treatment of non scalp areas
    One application to the affected area once daily. Recommended treatment period is 8 weeks. Subsequent courses should be initiated after medical review.

    One application to the affected areas once daily. The recommended treatment period is up to 8 weeks. Discontinue treatment when control is achieved. Allow 8 hours between the application and showering. Immediate shower or bath is not recommended after application.
    Treat on all affected scalp areas.


    Children aged 12 to 18 years (unlicensed):
    Total maximum 75g weekly when different calcipotriol preparations are used together.

    Stable plaque psoriasis and mild to moderate psoriasis
    Gel/ointment: Apply once daily to a maximum of 30% of body surface for up to 4 weeks.

    Scalp psoriasis
    Gel: 1g to 4g applied to scalp once daily, shampoo off after leaving on scalp overnight or during the day. Usual duration of therapy is 4 weeks.


    Children under 12 years
    Concurrent ultraviolet light therapy
    Open wounds
    Acne vulgaris
    Disorder of calcium metabolism
    Erythrodermic exfoliative psoriasis
    Fragile skin veins
    Perioral dermatitis
    Pustular psoriasis
    Severe hepatic disorder
    Severe renal impairment
    Skin atrophy
    Skin infection
    Skin manifestation of tuberculosis
    Skin ulcer
    Striae atrophicae

    Precautions and Warnings

    Children aged 12 to 18 years
    Diabetes mellitus

    Patients with diabetes may experience fluctuations in blood glucose
    Unsuitable for widespread small lesions, pustular or acute psoriasis
    Not all available brands are licensed for all indications
    Some formulations contain butylated hydroxy toluene (E321)
    Some formulations contain butylhydroxyanisole (E320)
    Some formulations contain macrogolglycerol hydroxystearate
    Advise patient not to apply to more than 30% body surface
    Advise patient to wash hands after use
    Avoid contact with eyes, lips or mouth
    Avoid contact with mucous membranes
    Avoid occlusive dressings
    Breastfeeding: Wash product off breasts prior to breastfeeding infant
    Do not apply to atrophic skin
    Do not apply to genitalia
    Do not apply to intertriginous skin
    Do not apply to large areas of abraded or damaged skin
    Not to be applied to the face
    Prolonged use/application to large areas of broken skin may inc. absorption
    If visual disturbances occur, perform ophthalmic evaluation
    Possible systemic absorption of steroid
    Increased risk of hypercalcaemia if maximum weekly dose of 100g exceeded
    Prolonged/excessive use may lead to adrenal suppression
    Rebound effect may occur after cessation of treatment
    Risk of generalised pustular psoriasis with use of topical corticosteroids
    Discontinue therapy and use antimicrobials if secondary infection occurs
    Maximum adult dose of calcipotriol from all formulations - 5mg per week
    Advise patient maximum daily dose should not be more than 15 grams
    Advise patient residue on clothing/bedding may cause fire hazard
    Avoid excessive exposure to sunlight
    Avoid excessive exposure to UV light
    Fire hazard: Keep away from naked flames and potential sources of ignition

    The risk of hypercalcaemia is minimal when the recommendations relevant to calcipotriol are fulfilled. Due to the content of calcipotriol, hypercalcaemia may occur if the maximum daily dose of 15 g of the gel and ointment is exceeded. Serum calcium is, however, quickly normalised when treatment is discontinued.

    The risk of systemic absorption of the steroid component is increased if occlusive dressings are used or if the preparation is applied to large areas or for prolonged periods to areas of damaged skin, on mucous membranes or skin folds. Long term corticosteroid use is associated with an increased risk of local and systemic adverse effects. If such effects occur, treatment should be discontinued. Adverse effects occurring following systemic corticosteroid use include adrenal cortex suppression or alterations to the metabolic control of diabetes mellitus.

    Some manufacturers advise patients to limit or avoid excessive exposure to natural and UV light.

    Avoid concurrent treatment with other steroids on the same treatment area.

    Pregnancy and Lactation


    Calcipotriol and betamethasone is contraindicated during pregnancy.

    The manufacturer suggests topical calcipotriol with betamethasone should only be used when the potential benefit justifies the potential risk. At the time of writing there is limited published information regarding the use of calcipotriol with betamethasone during pregnancy. Animal studies with glucocorticoids have shown reproductive toxicity, but a number of epidemiological studies have not revealed congenital anomalies. The potential risk for humans is uncertain.


    Use calcipotriol with betamethasone with caution during breastfeeding.

    The manufacturer advises caution if calcipotriol with betamethasone is used when breastfeeding. There are no data are available, at the time of writing, on the use of calcipotriol with betamethasone whilst breastfeeding. Betamethasone passes into breast milk, but the risk of adverse effects on the nursing infant appears to be unlikely at therapeutic doses. At the time of writing, there is no published experience concerning the use of calcipotriol during breastfeeding. The breast area should be wiped off prior to nursing if there has been any topically applied corticosteroid.


    Advise patient to avoid application and accidental transfer of the ointment or foam to the scalp, face, mouth and eyes. The gel may be used to treat scalp lesions but application of the gel and the cream to the face, mouth or eyes should be avoided.

    Advise patient or carer to wash their hands after each application to avoid transfer of the preparation to untreated areas.

    Advise patient to avoid excessive exposure to natural or artificial sunlight during therapy.

    Side Effects

    Adrenal cortex insufficiency
    Allergic contact dermatitis
    Application site reaction
    Atrophy (localised)
    Blurred vision
    Burning sensation
    Central serous chorioretinopathy
    Colloid milia
    Decreased glycaemic control in diabetes
    Depigmentation of hair
    Dry skin
    Exacerbation of psoriasis
    Eye irritation
    Facial oedema
    Hypersensitivity reactions
    Increased intra-ocular pressure
    Mucosal irritation
    Perioral dermatitis
    Pustular psoriasis
    Pustular rash
    Skin depigmentation
    Skin exfoliation
    Skin infection
    Skin irritation
    Skin pain
    Visual disturbances


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last full review: September 2020

    Reference Sources

    Summary of Product Characteristics: Dalbecal 50 microgram/g + 0.5mg/g ointment. Teva UK Ltd. Revised September 2019.
    Summary of Product Characteristics: Dalonev ointment. Mibe Pharma UK Ltd. Revised August 2020.
    Summary of Product Characteristics: Dovobet gel. Leo Laboratories Limited. Revised August 2019.
    Summary of Product Characteristics: Dovobet ointment. Leo laboratories Limited. Revised August 2018.
    Summary of Product Characteristics: Enstilar 50 micrograms/g + 0.5 mg/g cutaneous foam. Leo Pharma. Revised February 2021.
    Summary of Product Characteristics: Wynzora 50 micrograms/g + 0.5mg/g cream. Almirall, S.A. Revised December 2021.

    NICE - Evidence Services
    Available at:
    Last accessed: 05 November 2021

    US National Library of Medicine. Toxicology Data Network. Drugs and Lactation Database (LactMed).
    Available at:
    Betamethasone, topical. Last revised: 31 October 2018
    Last accessed: 11 September 2020

    US National Library of Medicine. Toxicology Data Network. Drugs and Lactation Database (LactMed).
    Available at:
    Calcipotriol Last revised: 10 March, 2015.
    Last accessed: 14 July, 2015.

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.